Literature DB >> 20046200

Connective tissue diseases: A nonsurgical therapy for Dupuytren disease.

Ardeshir Bayat.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20046200     DOI： 10.1038/nrrheum.2009.255

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

Review 1.  Nonoperative treatment of Dupuytren's disease.

Authors:  L C Hurst; M A Badalamente
Journal:  Hand Clin       Date:  1999-02       Impact factor: 1.907

Review 2.  Assessment of clinical severity in Dupuytren's disease.

Authors:  A Bayat; E J Cunliffe; D A McGrouther
Journal:  Br J Hosp Med (Lond)       Date:  2007-11       Impact factor: 0.825

Review 3.  Management of Dupuytren's disease--clear advice for an elusive condition.

Authors:  A Bayat; D A McGrouther
Journal:  Ann R Coll Surg Engl       Date:  2006-01       Impact factor: 1.891

4.  Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence.

Authors:  Sandip Hindocha; John K Stanley; Stewart Watson; Ardeshir Bayat
Journal:  J Hand Surg Am       Date:  2006-12       Impact factor: 2.230

5.  Enzyme injection as nonsurgical treatment of Dupuytren's disease.

Authors:  M A Badalamente; L C Hurst
Journal:  J Hand Surg Am       Date:  2000-07       Impact factor: 2.230

6.  Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.

Authors:  Marie A Badalamente; Lawrence C Hurst; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2002-09       Impact factor: 2.230

7.  The heritability of Dupuytren's disease: familial aggregation and its clinical significance.

Authors:  Sandip Hindocha; Sally John; John K Stanley; Stewart J Watson; Ardeshir Bayat
Journal:  J Hand Surg Am       Date:  2006-02       Impact factor: 2.230

8.  Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

Authors:  Lawrence C Hurst; Marie A Badalamente; Vincent R Hentz; Robert N Hotchkiss; F Thomas D Kaplan; Roy A Meals; Theodore M Smith; John Rodzvilla
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245

9.  Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture.

Authors:  Marie A Badalamente; Lawrence C Hurst
Journal:  J Hand Surg Am       Date:  2007 Jul-Aug       Impact factor: 2.230
  9 in total
  2 in total

1.  In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.

Authors:  Farhatullah Syed; Alexis N Thomas; Subir Singh; Venkatesh Kolluru; Susan G Emeigh Hart; Ardeshir Bayat
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

2.  First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and Xiapex.

Authors:  Syed Amir Iqbal; Michael John Hayton; James Stewart Watson; Piotr Szczypa; Ardeshir Bayat
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.